Valeant Pharmaceuticals International, Inc. Form 8-K May 02, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
May 2, 2011

Valeant Pharmaceuticals International, Inc.

(Exact name of registrant as specified in its charter)

Canada001-1495699-0448205(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.

7150 Mississauga Road Mississauga, Ontario Canada

(Address of principal executive offices)

L5N 8M5

(Zip Code)

(905) 286-3000

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 8-K

Item 8.01. Other Events.

On May 2, 2011, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

99.1 Press Release, dated May 2, 2011

Page 2 of 3 Pages

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Valeant Pharmaceuticals International, Inc.

(Registrant)

Date: May 2, 2011 By: /s/ Robert Chai-Onn

Name: Robert Chai-Onn

Title: Executive Vice President, General Counsel and Corporate Secretary

Page 3 of 3 Pages